New asthma drug! Two phase III clinical studies of fevipiprant (qaw039), a DP2 receptor antagonist of Novartis, failed!

December 17, 2019 / BIOON / -- Novartis recently released the latest results of the key global phase III study of the new asthma drug fevipiplant (qaw039) on luster-1 and luster-2 These studies explored the efficacy and safety of the DP2 receptor antagonist fevipiprant Summary analysis showed that during the 52 week treatment period, two doses of fevipiprant (150mg / 450mg) did not reach the clinical related threshold of reducing the rate of moderate and severe deterioration compared with placebo These studies included patients with moderate to severe asthma (GINA level 4 or 5) who were not adequately controlled despite receiving inhaled corticosteroids (ICS) of medium to high doses and at least one additional control drug Fevipiprant is a new and non steroidal drug, which can block the DP2 pathway It is a potential regulator of the inflammatory cascade in asthma Novartis said the overall results from the two studies do not support further clinical development of fevipiprant in the treatment of asthma In these studies, the tolerance of fevipiprant is generally good, and the adverse reactions caused by treatment are generally balanced among groups, which is equivalent to placebo Novartis is currently analyzing detailed efficacy and safety data from the luster-1 and luster-2 studies, which will be presented to the upcoming medical conference John Tsai, director of global drug development and chief medical officer of Novartis, said: "while it is disappointing to evaluate the results of these luster studies on fevipiprant in the treatment of asthma, they help us understand the DP2 pathway in asthma We are very grateful to all the patients, their families and investigators who participated in these studies and contributed greatly to them " The molecular structure formula of fevipiprant (drugbank CA) luster-1 and luster-2 are two repetitive studies, which are part of vibrant phase III project The project also includes spirit security studies and complementary repeat zeal-1 and zeal-2 studies In October, Novartis released the latest results of zeal-1 and zeal-2 Novartis will continue to invest in the assets of respiratory diseases, including the listed products xolair ® (severe allergic asthma [SAA] and chronic spontaneous urticaria [CSU]) and ultibro ® breezhaler ® 8 (COPD) as well as the research drugs qvm1499 (moderate and severe asthma) and qmf14910 (moderate and severe asthma) in phase III clinical development stage, and will continue to promote including asthma , COPD, and other high demand areas such as idiopathic pulmonary fibrosis and sarcoidosis Novartis provides update on luster phase III students in patients with uncontrolled Gina 4 / 5 ASTM A